1. Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine.
- Author
-
Xavier, Cristina P.R., Castro, Inês, Caires, Hugo R., Ferreira, Dylan, Cavadas, Bruno, Pereira, Luisa, Santos, Lúcio L., Oliveira, Maria J., and Vasconcelos, M. Helena
- Subjects
- *
EXTRACELLULAR vesicles , *PANCREATIC cancer , *MACROPHAGES , *CHITINASE , *FIBRONECTINS , *CELL communication , *PANCREATIC tumors , *PYRIDINE , *BIOCHEMISTRY , *RESEARCH , *RESEARCH methodology , *DEOXYCYTIDINE , *CELL physiology , *MEDICAL cooperation , *EVALUATION research , *DUCTAL carcinoma , *PROTEOMICS , *PHENOMENOLOGY , *COMPARATIVE studies , *SURVIVAL analysis (Biometry) , *GENES , *PENTOXIFYLLINE , *CELL lines , *DRUG resistance in cancer cells , *PHARMACODYNAMICS - Abstract
Tumour-associated macrophages have been implicated in pancreatic ductal adenocarcinoma (PDAC) therapy response and Extracellular vesicles (EVs) shed by macrophages might have a role in this process. Here, we demonstrated that large EVs released by anti-inflammatory human macrophages decreased PDAC cellular sensitivity to gemcitabine. Using proteomic analysis, chitinase 3-like-1 (CHI3L1) and fibronectin (FN1) were identified as two of the most abundant proteins in the cargo of macrophages-derived EVs. Overexpression of CHI3L1 and FN1, using recombinant human proteins, induced PDAC cellular resistance to gemcitabine through ERK (extracellular-signal-regulated kinase) activation. Inhibition of CHI3L1 and FN1 by pentoxifylline and pirfenidone, respectively, partially reverted gemcitabine resistance. In PDAC patient samples, CHI3L1 and FN1 were expressed in the stroma, associated with the high presence of macrophages. The Cancer Genome Atlas analysis revealed an association between CHI3L1 and FN1 gene expression, overall survival of PDAC patients, gemcitabine response, and macrophage infiltration. Altogether, our data identifies CHI3L1 and FN1 as potential targets for pharmacological inhibition in PDAC. Further pre-clinical in vivo work is warranted to study the possibility of repurposing pentoxifylline and pirfenidone as adjuvant therapies for PDAC treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF